IP Library Granted Patent US 10,253,333
Granted Patent B2
US 10,253,333 · App. 15/709,969 · Granted Apr 9, 2019

DNA-binding proteins and uses thereof

Inventors: Philip D. Gregory (Richmond, CA); Jeffrey C. Miller (Richmond, CA); David Paschon (Richmond, CA); Edward J. Rebar (Richmond, CA); Siyuan Tan (Richmond, CA); Fyodor Urnov (Richmond, CA); Lei Zhang (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/907C07K14/195C12N9/22C12N15/52C12N15/62C12N15/8213C12N15/85C12Y301/21004A61K38/00C07K2319/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,253,333
App. No.
15/709,969
Granted
Apr 9, 2019
Kind
B2
Abstract

Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.

Claims (13)

1. An isolated, non-naturally occurring TALE DNA-binding polypeptide comprising:

two or more TALE-repeat units, the TALE repeat units comprising a repeat variable di-residue (RVD); and wherein the N-terminal region lacks at least 152 amino acids of a full-length TALE protein and the C-terminal region is truncated to residue C+63, and further wherein the polypeptide binds to DNA.

2. The polypeptide of claim 1 , wherein at least one TALE-repeat unit comprises an atypical repeat variable di-residue (RVD).

3. The polypeptide of claim 2 , wherein the polypeptide comprises an atypical RVD as shown in Tables 27A or 27B.

4. The polypeptide of claim 1 , wherein the N-terminal region is truncated to residue N+134 to residue N+137.

5. The polypeptide of claim 1 , wherein the C-cap comprises a TALE repeat domain.

6. The polypeptide of claim 1 , further comprising a functional domain.

7. The polypeptide of claim 6 , wherein the functional domain is a transcriptional activator or a transcriptional repressor.

8. The polypeptide of claim 1 , wherein the functional domain comprises a nuclease domain.

9. The polypeptide of claim 8 , wherein the nuclease domain is an endonuclease domain.

10. An isolated cell comprising the polypeptide of claim 1 .

11. A pharmaceutical composition comprising the cell according to claim 10 .

12. A pharmaceutical composition comprising the polypeptide according to claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2022
From: GREGORY, PHILIP D.; MILLER, JEFFREY C.; PASCHON, DAVID; REBAR, EDWARD J.; TAN, SIYUAN; URNOV, FYODOR; ZHANG, LEI
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 060674/0666 →
CHANGE OF NAME Recorded Jul 29, 2022
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 061034/0215 →
Continuity (10)
Continuation 15284164 · Oct 3, 2016
Continuation 14065028 · Oct 28, 2013
Division 13068735 · May 17, 2011
Provisional Application 61395836 · May 17, 2010
Provisional Application 61401429 · Aug 12, 2010
Provisional Application 61455121 · Oct 13, 2010
Provisional Application 61459891 · Dec 20, 2010
Provisional Application 61462482 · Feb 2, 2011
Provisional Application 61465869 · Mar 24, 2011
Related Publication 20180010152A1 · Jan 11, 2018